Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
06/2003
06/26/2003US20030119859 Useful in the prophylaxis and treatment of respiratory diseases
06/26/2003US20030119856 Thiazole compounds useful as inhibitors of protein kinase
06/26/2003US20030119825 Highly concentrated stable meloxicam solutions for needleless injection
06/26/2003US20030119802 Use particularly in the prophylaxis and treatment of respiratory diseases.
06/26/2003US20030119801 Stabilized tibolone compositions
06/26/2003US20030119794 Also containing an acetylsalicylate anionand a beta-receptor blocker or a hypertensive agent; especially treating cardiac arrest, angina and shock
06/26/2003US20030119783 Aqueous compositions containing metronidazole
06/26/2003US20030119768 Reducing toxicity by treating the oligonucleotide in multimeric aggregate form to convert all of it to a monomeric form and to prevent the formation of aggregates before administration
06/26/2003US20030119761 Glycosyl CNS acting prodrug compound covalently N-linked with a saccharide through an amide or an amine bond; neuraxial drug delivery
06/26/2003US20030119735 Delivery system
06/26/2003US20030119734 GLP-1(7-37) or an analogue wherein an amino acid residue of the parent peptide has a lipophilic substituent attached optionally via a spacer; pH is 7-10
06/26/2003US20030119728 Stable, nasally, orally or sublingually applicable pharmaceutical preparation
06/26/2003US20030119725 Internalization by a broad host cell spectrum; delivery of diagnostics and therapeutics
06/26/2003US20030119724 Contain a hepatic ligand to direct an oligomer or "payload" to a hepatocyte intracellularly via a receptor-mediated, ligand-directed pathway; solid phase synthesis
06/26/2003US20030119719 Use of endothelin conjugates in therapy, new endothelin conjugates, agents that contain the latter, and process for their production
06/26/2003US20030119718 Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
06/26/2003US20030119684 Conditioning solution for contact lenses and a method of using the same
06/26/2003US20030119189 Method for delivery of molecules to intracellular targets
06/26/2003US20030119188 Novel compounds
06/26/2003US20030119078 Method of reducing immunogenicity of toxicity of an antibody of IgG class
06/26/2003US20030119070 Complexing ligand, peptide ; displacement of one ligand with another
06/26/2003US20030118669 Novel substituted benzimidazole dosage forms and method of using same
06/26/2003US20030118666 Injectable solution containing a shark-derived chondroitin sulfate iron colloid
06/26/2003US20030118660 Residual solvent extraction method and microparticles produced thereby
06/26/2003US20030118657 Treatment of disease states characterized by excessive or inappropriate angiogenesis
06/26/2003US20030118654 Taste masked aqueous liquid pharmaceutical composition
06/26/2003US20030118652 Methods and compositions for use of (S)-bisoprolol
06/26/2003US20030118648 Two combined tablet portions, with different releasing rates; drug delivery providing immediate, sustained and prolonged release
06/26/2003US20030118644 A solid forms comprising low molecular weight peptide-based thrombin inhibitor having pH dependent solubility, cellulose or starch as disintegrant fillers; immediate release
06/26/2003US20030118642 Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
06/26/2003US20030118641 Abuse-resistant sustained-release opioid formulation
06/26/2003US20030118640 Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate
06/26/2003US20030118638 Oral pharmaceutical products containing 17 beta-estradiol-3-lower alkanoate, method of administering the same and process of preparation
06/26/2003US20030118629 Water-in-oil emulsions with anionic groups, compositions, and methods
06/26/2003US20030118618 Dialkyl fumarate, a polyethyleneglycol dihydroxystearate and an alkyl monoethanolamide
06/26/2003US20030118612 G-CSF conjugates
06/26/2003US20030118610 Oral delivery of peptides using enzyme-cleavable membrane translocators
06/26/2003US20030118600 Transfer compounds, production and use thereof
06/26/2003US20030118598 Botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising botulinum toxin and recombinant albumin, suitable for therapeutic administration to humans
06/26/2003US20030118595 Supramolecular bioconjugates
06/26/2003US20030118594 Stable formulations of mhc-peptide complexes
06/26/2003US20030118569 Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells
06/26/2003US20030118553 Vector constructs for gene-therapy mediated radionuclide therapy of undifferentiated and medullary thyroid carcinomas and non-thyroidal tumours and metastases mediated thereof
06/26/2003US20030118548 Aqueous solution containing glycerin buffer; controlling pH; freeze drying; mutiple sclerosis therapy
06/26/2003US20030118547 Composition for intestinal delivery
06/26/2003US20030118540 Composition
06/26/2003US20030118536 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003US20030118528 Topical delivery of codrugs
06/26/2003US20030118514 Compositions for inhalation
06/26/2003US20030118513 Lung administering; bioavailability
06/26/2003US20030118512 Volatilization of a drug from an inclusion complex
06/26/2003US20030118511 Skin disorders; psoriasis
06/26/2003US20030118510 Immobilization of insulin; antidiabetic agents
06/26/2003US20030118507 Methods of using 46828, a human acyl-CoA synthetase
06/26/2003CA2822457A1 Methods and compositions for controlled resease of drugs
06/26/2003CA2497195A1 Methods and compositions for controlled release of drugs
06/26/2003CA2471589A1 Pharmaceutical conjugates with enhanced pharmacokinetic characteristics
06/26/2003CA2471260A1 Compositions and methods for high sorption of skin materials and delivery of sulfur
06/26/2003CA2471251A1 Method of enhancing immunogenicity by covalent linkage of antigens to proteins on the surface of dendritic cells
06/26/2003CA2470629A1 Stabilized brivudine topical formulations
06/26/2003CA2470590A1 Pharmaceutical composition comprising an oil/water/oil double microemulsion incorporated into a solid support
06/26/2003CA2470582A1 Mitocidal compositions and methods
06/26/2003CA2470472A1 Aqueous ifosfamide composition
06/26/2003CA2470419A1 Growth factor modified protein matrices for tissue engineering
06/26/2003CA2470377A1 Solid dosage form for the ocular administration of an active principle, a soluble, solid ophthalmic insert and the production method thereof
06/26/2003CA2470322A1 Methods for particle-assisted polynucleotide immunization using a pulsed electric field
06/26/2003CA2470209A1 Pre-formulation for the tabletting of natural mixtures of conjugated estrogens
06/26/2003CA2469799A1 Use of a lysolipid for the preparation of a composition for transfection of a polynucleotide into a cell
06/26/2003CA2469663A1 Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
06/26/2003CA2469205A1 Bioadhesive drug delivery system with enhanced gastric retention
06/26/2003CA2468687A1 Liquid bisphosphonate formulations for bone disorders
06/26/2003CA2465888A1 Topical compositions and methods for treatment of adverse effects of ionizing radiation
06/26/2003CA2453417A1 Nanoparticle delivery vehicle
06/25/2003EP1321516A2 Hydrogel matrix for cellular tissue storage
06/25/2003EP1321466A1 Haptens, immunogens, antibodies and conjugates for 2-oxo-3-hydroxy LSD
06/25/2003EP1321159A1 Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
06/25/2003EP1321150A1 Pharmaceutical composition for treatment of premature ejaculation and/or hypersensitivity of sexual stimulation
06/25/2003EP1321147A1 Orally administrable solid ribavirin dosage forms and process for making them
06/25/2003EP1321144A1 Eye drops
06/25/2003EP1321142A1 Solid pharmaceutical composition for oral administration of Tegaserod
06/25/2003EP1320710A1 Drying method for selectively removing volatile components from wet coatings
06/25/2003EP1320589A2 Antiangiogenic polypeptides and methods for inhibiting angiogenesis
06/25/2003EP1320551A1 The identification and development of specific monoclonal antibodies to squamous cell carcinoma
06/25/2003EP1320549A2 Pumpcn compositions and uses thereof
06/25/2003EP1320412A1 Microcapsule powder
06/25/2003EP1320387A2 Pharmaceutical compositions for sustained drug delivery
06/25/2003EP1320386A1 A novel cationic lipopolymer as biocompatible gene delivery agent
06/25/2003EP1320385A1 Combination compositions
06/25/2003EP1320376A2 Treatment of prostate cancer
06/25/2003EP1320371A2 Charged phospholipid compositions and methods for their use
06/25/2003EP1320368A1 Infusion of ciprofloxacin having reduced acid content and being stable in storage
06/25/2003EP1320362A1 Stabilised fibrate microparticles
06/25/2003EP1320359A2 Thermogelling biodegradable aqueous polymer solution
06/25/2003EP1320357A1 Topical polymeric antimicrobial emulsion
06/25/2003EP1320356A2 Preparation of vitamin emulsions and concentrates thereof
06/25/2003EP1320353A2 Oil in glycerin emulsion
06/25/2003EP1320295A1 Collagen/polysaccharide bilayer matrix
06/25/2003EP1283725A4 Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
06/25/2003EP1263470B1 METHOD FOR PRODUCING A COENZYME Q10 / $g(g)-CYCLODEXTRIN COMPLEX
06/25/2003EP1250343B1 Azalide antibiotic compositions
1 ... 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 ... 1712